Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953786 | 1.00 | CA2 (0.46) | CA2CA1ALDH1A1CTBP2CA9 | |
| SCHEMBL2052029 | 0.89 | NPC1 (0.44) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL2052031 | 0.89 | NPC1 (0.44) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL9898038 | 0.88 | CA2 (0.45) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL9898039 | 0.88 | CA2 (0.45) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL11110696 | 0.84 | CTBP2 (0.59) | CA2CA1ALDH1A1CTBP2CA9 | |
| SCHEMBL11110698 | 0.84 | CTBP2 (0.59) | CA2CA1ALDH1A1CTBP2CA9 | |
| SCHEMBL7786991 | 0.83 | CA2 (0.44) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL7786989 | 0.83 | CA2 (0.44) | CA2CA1ALDH1A1CA9PPARG | |
| SCHEMBL23780246 | 0.83 | CA2 (0.46) | CA2CA1ALDH1A1CTBP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010130708-A9 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CA2 1547/4885CA1 2757/4885ALDH1A1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.